Introduction
Extubation failure, defined as the need for reintubation within 24 to 72 hours after planned extubation, is associated with poor outcomes [1] . The reported mortality was 20% to 40%, which is 2.5 to 10 times higher than the mortality in successfully extubated patients [2] [3] [4] . Extubation failure is also associated with increased length of stay in the intensive care unit (ICU) and in hospital overall, and increased total hospital costs [2, 5] . The reported prevalence of extubation failure is 5% to 25% depending on the patient population, weaning assessment method, and duration of follow up [2] [3] [4] [5] [6] [7] . Medical critically ill patients, elderly patients, patients with re spiratory failure caused by severe pneumonia, and those with preexisting heart and lung disease or fluid accumulation are considered to be at higher risk of extubation failure [1, 8] .
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Noninvasive ventilation (NIV) had been used to prevent reintubation in patients at high risk of extubation failure. Data from small-to moderate-sized randomized controlled studies suggest that NIV-assisted extubation could prevent reintubation, especially in patients with chronic obstructive lung disease (COPD) and congestive heart failure [9] [10] [11] . A recent meta-analysis reported that NIV significantly reduced the reintubation rate compared with conventional treatment in patients with COPD and others at high risk of extubation failure but not in medical critically ill patients [12] . However, a randomized controlled trial reported increased mortality among patients who received NIV for the treatment of acute respiratory failure, which developed postextubation [13] . These suggested that delay in NIV use after extubation or after development of respiratory failure was not effective in preventing reintubation.
Most medical critically ill patients have high-risk features for developing extubation failure. The risks include COPD, congestive heart failure, aging, fluid accumulation, impaired mental status, and multiple comorbid conditions. NIV is currently applied widely after extubation to prevent the need for reintubation in mixed medical critically ill patients despite a lack of evidence to support its use. However, the specific patient characteristics that may make them unsuitable for NIV to prevent reintubation have not been evaluated. We conducted a descriptive cohort study in our medical ICU to identify factors predictive of failure of NIV-assisted extubation among medical critically ill patients.
Materials and methods

Study design
This study was an observational, descriptive, retrospective, cohort study that enrolled medical critically ill patients who were admitted to medical ICUs at Siriraj Hospital between March 2012 and August 2015. The study protocol was approved by the Siriraj Institutional Review Board, Siriraj Hospital, Mahidol University. The certificate of approval code was 428/2557 (EC3).
Patients
We included the patients who met the following criteria: age at least 18 years, respiratory failure depended on mechanical ventilation for more than 48 hours, successful extubation, and the attending physician decided to use NIV to prevent extubation failure. Patients with tracheostomy, postoperative abdominal surgery, increased intracranial pressure, or facial wounds or deformities that prohibited the application of an NIV facemask were excluded from the study.
NIV was initiated according to the decision of the attending physician. The application of NIV is aimed to prevent the respiratory failure from the following causes: hypercapnic respiratory failure, hypoxemic respiratory failure, respiratory muscle fatigue, and upper airway obstruction. For NIV interface, a facial mask, covering either the patient's nose or the patient's nose and mouth, or a total mask, covering the entire patient's face, was used and adjusted for acceptable air leakage (b20%). The bilevel positive pressure mode was used with a starting inspiratory pressure of 6 to 10 cm H 2 O and expiratory pressure of 4 to 6 cm H 2 O. The pressure was adjusted to maintain the tidal volume at 7 to 10 mL/kg. The inspiratory O 2 fraction was adjusted to maintain the oxygen saturation greater than 94%. The duration of NIV-assisted venti lation was under the control of the attending physician.
Data collection
We recorded the patients' characteristics, including underlying conditions, ICU admission diagnosis, causes of respiratory failure, and baseline laboratory parameters. Disease severity was recorded at ICU admission according to the Acute Physiologic Assessment and Chronic Health Evaluation II (APACHE II) system and the Sepsis-related Organ Failure Assessment (SOFA) score at ICU admission and immediately before NIV application. Vital signs, hemodynamic parameters, and respiratory parameters derived from the mechanical ventilator (Respironics, Herrsching, Germany) were recorded according to ICU nursing care standards. Treatments during ICU admission, especially fluid therapy and administration of sedative, analgesic, and paralytic agents, were recorded. The decision to terminate NIV-assisted extubation and reintubation was recorded. The indication for reintubation, following standards of ICU care, included loss of patient consciousness, cardiopulmonary arrest, refractory hypoxemia (O 2 saturation b90%), unable to clear airway secretion, and decision of the attending physician to reintubate.
Outcome assessment
The enrolled patients were classified as having successful NIVassisted extubation if they did not receive reintubation during ICU admission. Patients were classified as having failure of NIV-assisted extubation if they required reintubation during ICU admission. The ICU mortality, 28-day mortality, and hospital mortality were recorded.
Statistical analysis
Statistical analysis was performed using SPSS version 18. Continuous variables were presented as mean ± standard deviation (SD), and categorical variables were presented as percentages. Differences between groups were analyzed by χ 2 tests for categorical variables and Student t tests for continuous variables. We plotted receiver operat ing characteristic (ROC) curves for continuous variables with significant differences between groups to identify the cutoff point for each variable. The optimal cutoff point for each variable of interest was determined by using the Youden index [14] . Continuous variables were then classified into positive or negative groups according to the cutoff point. We per formed univariate analysis for individual categorical variables, and var iables with a value of P b .1 were included in the multivariate model using binary logistic regression analysis. A value of P b .05 was consid ered to be significant.
Results
Patient characteristics
A total of 105 patients met the eligibility criteria and were enrolled in the study from March 2012 to August 2015. The mean patient age was 63.3 ± 17.9 years, and 48 patients (45.7%) were female. The most common underlying conditions were hypertension (56.2%) and diabe tes mellitus (40%). COPD was only documented in 9% of patients. The leading ICU admission diagnoses were pneumonia (65.7%) and shock (63.8%, mostly septic shock). The reintubation rate was 45.7%, and these patients were classified as the failure group. The patient charac teristics are shown in Table 1 .
There was no significant difference in patient age, sex, body size, un derlying condition, or cause of respiratory failure between the groups. However, baseline APACHE II and SOFA scores after extubation/before initiating NIV were higher in the NIV failure group. Significantly more patients in the failure group had an ICU admission diagnosis of pneumo nia compared with the successful NIV group. The vital signs and results of arterial blood gas analysis during weaning and after application of NIV for 1 hour are shown in Table 2 . There were no significant differences in mean arterial blood pressure or any arterial blood gas parameters between the 2 groups. However, patients who failed NIV and required reintubation had significantly higher heart rates than patients who were successfully extubated.
Treatment modalities and ventilator variables
Patients in the failure group had significantly more fluid accumulation per kilogram compared with the successful group (229.9 ± 243.7 vs 93.9 ± 118.4 mL/kg body weight, P b .001). Other treatment modalities, including use of vasopressors, analgesic and sedative agents, muscle relaxants, and renal replacement therapy, did not differ significantly between the groups. The duration of invasive mechanical ventilator dependence, mode of weaning (T-piece vs pressure support), and weaning duration were similar in both groups ( Table 3 ). The time from extubation to the initiation of NIV (9.9 ± 19.1 vs 4.4 ± 7.9 hours, P = .05) and the duration of NIV-assisted ventilation (98.1 ± 93.8 vs 64.8 ± 62.0 hours, P = .03) were significantly longer among the failed compared with the successful NIV group.
Predictors of NIV failure
We investigated the parameters that differed significantly between the groups to identify the predictive factors associated with failure of NIV-assisted extubation. ROC curves of continuous variables were used to identify the cutoff points. Because APACHE II score on the day of extubation was unavailable, we used the SOFA score measured before NIV application to represent the baseline severity score. In terms of heart rate, we used the heart rate after application of NIV for 1 hour. ROC curves were also generated for fluid accumulation, time from extubation to the initiation of NIV, and duration of NIV application. The cutoff points derived from ROC curves were as follows: SOFA score greater than 3.5, heart rate after NIV for 1 hour of more than 100 beats per minute, time from extubation to NIV initiation of more than 12 hours, overall NIV duration of more than 96 hours, and fluid accumu lation greater than 100 mL/kg. These variables were subjected to uni variate analysis according to their respective cutoff points. Parameters with P ≤ .1, together with an ICU admission diagnosis of pneumonia, were included in the multivariate analysis model. The results of univariate and multivariate analyses are shown in Table 4 . Only pneu monia as the cause of ICU admission was identified as an independent predictive factor associated with failure of NIV-assisted extubation (odds ratio, 2.8; 95% confidence interval [CI], 1.08-2.32; P = .03). (See Table 5 .)
Patient outcome: mortality
Reintubated patients had significantly higher hospital mortality than successfully extubated patients (50% vs 1.8%, respectively; P b .001). No patients in the successfully extubated group died during ICU admission or within 28 days.
Discussion
The results of this study demonstrated a 45.7% reintubation rate among medical critically ill patients who received NIV support after planned extubation. Pneumonia as the ICU admission diagnosis was the only significant independent factor predicting failure of NIVassisted extubation. Other potential predictors included prolonged NIV for more than 96 hours after extubation and fluid accumulation greater than 100 mL/kg. Patients with failed NIV-assisted extubation had significantly higher mortality than successfully extubated patients. The incidence of reintubation in this study, despite NIV support, was higher than in previous studies without NIV [2] [3] [4] . This could be ex plained by differences in patients' baseline characteristics. Older age, mostly older than 65 years, and APACHE II score greater than 12 were reported to be independent predictive factors for extubation failure among critically ill patients and post-cardiac surgery patients [1, 2, 15] . Higher proportions of patients with underlying chronic respiratory dis ease, ischemic heart disease, and a diagnosis of congestive heart failure at ICU admission also increased the risk of reintubation [15] . Patients with previous ischemic stroke were associated with altered levels of consciousness, increased risk of aspiration, and compromised airway protection, resulting in increased risk of extubation failure [8] . A high proportion of patients with pneumonia as the ICU admission diagnosis was also previously reported as a predictor of extubation failure [1, 8] .
Current evidence supports the use of NIV for preventing reintubation in patients with specific characteristics associated with high risk of extubation failure. Ferrer et al [9] reported on a randomized controlled trial comparing NIV support after planned extubation with conventional oxygen therapy in high-risk ICU patients who were intubated for more than 48 hours. The risks included age more than 65 years, APACHE II score greater than 12 on the extubation day, and re spiratory failure caused by cardiac failure. They found that immediate NIV support for 24 hours after extubation was associated with a lower incidence of postextubation respiratory failure. Although the NIVsupport group had lower ICU mortality, there was no significant differ ence in hospital mortality between the groups. The mortality benefit of NIV was observed in a subgroup of patients with chronic respiratory disorders with hypercapnic respiratory failure. The benefit of NIV in preventing reintubation in patients with chronic respiratory disorders with hypercapnic respiratory failure was confirmed by Ferrer et al [10] , who randomly assigned hypercapnic respiratory failure patients able to tolerate a spontaneous breathing trial to receive either NIV sup port after extubation for 24 hours or conventional oxygen therapy. They reported an association between lower respiratory failure rate after extubation and lower 90-day mortality among the NIV-support group.
In another study, Nava et al enrolled patients at high risk of reintubation, defined by the presence of hypercapnia, congestive heart failure, ineffective cough and excessive tracheobronchial secretions, at least 2 failed weaning trials, at least 2 comorbid conditions, and upper airway obstruction [11] . The patients were randomized into an NIV-support group, who received NIV for at least 8 h/d within 48 hours after extubation, and a standard medical therapy group. NIV support was associated with a significantly lower reintubation rate (4/48 vs 12/49, P = .027) and reduced ICU mortality but had no effect on hospital mortality.
In contrast to these previous studies, Su et al [16] reported a nonfavorable outcome of NIV support among medical critically ill patients, with a reintubation rate of 10.5% in the NIV-support group compared with 8% in the conventional-therapy group. However, these results may reflect the low risk for reintubation in the study population.
Esteban et al [13] reported a high failure rate of NIV support among patients who developed respiratory failure after extubation within 48 hours. The reintubation rates were 48% in both the NIV and standardtherapy groups. This study raised concerns about delayed reintubation in the NIV group, which may have been responsible for the higher ICU mortality among the NIV-support compared with the standardtherapy group.
The different results in terms of the ability of NIV to prevent respiratory failure and reintubation after extubation may be explained by differences in the study populations.
Studies reporting beneficial effects of NIV in preventing respiratory failure enrolled a higher proportion of patients with chronic respiratory disorders, ranging from 34% to 100% [9] [10] [11] [12] , compared with only 10% in trials reporting negative results [13, 16] . Acute exacerbation of chronic respiratory disease and hypercapnic respiratory failure were the leading causes of respiratory failure among patients in the NIV-benefit trials, whereas pneumonia was reported as the cause of respiratory failure in only 10% to 18% of patients. Delayed NIV support was also considered to affect the success of NIV in preventing respiratory failure. All the studies that reported positive results applied NIV immediately after extubation and before the patient developed respiratory distress [9] [10] [11] [12] 15] , whereas studies with negative results started NIV in patients who had already developed symptoms and signs of respiratory failure [13] .
The population in our study differed from those in previous studies. Firstly, COPD was documented in only 9.5% of patients, and secondly, pneumonia was the most common ICU admission diagnosis, and the most common cause of respiratory failure was hypoxemic respiratory failure, which occurred in 67.4% of the patients. Thirdly, hypercapnic respiratory failure was the cause of respiratory failure in only 24.7% of patients. These factors may explain the high incidence of NIV failure in preventing postextubation respiratory failure.
Regarding the factors predicting failure of NIV support to prevent reintubation, univariate analysis identified SOFA score before NIV greater than 3.5, ICU admission diagnosis of pneumonia, heart rate after NIV for 1 hour of more than 100 beats per minute, delay from extubation to initiation of NIV of more than 12 hours, fluid accumulation greater than 100 mL/kg, and NIV duration more than 96 hours as significant predictors. However, multivariate analysis only identified an ICU admission diagnosis of pneumonia as an independent predictor of reintubation despite NIV support.
Noninvasive positive pressure ventilation may benefit patients who require low to moderate levels of positive pressure ventilation. The greatest benefits of NIV have been reported in patients with hypercap nic respiratory failure associated with COPD [17] , followed by conges tive heart failure [18] , and in postoperative patients [19] . Positive pressure during inspiration may reduce the work of breathing, rest exhausted respiratory muscles, and compensate for increased airway resistance. Positive pressure during expiration reduces venous return and prevents respiratory failure in patients with congestive heart fail ure. All these effects improve ventilation and perfusion matching and promote carbon dioxide clearance.
ICU, hospital, and 28-day mortalities were significantly higher in pa tients who required reintubation in the current study. Hospital mortal ity associated with reintubation after failure of NIV support was 50%, compared with 30% to 40% in a previous study with no NIV support [1] [2] [3] [4] . The delay in reintubation in NIV-supported patients may increase overall mortality, as reported in a randomized controlled study by Esteban et al [13] .
This study had certain limitations. First, its retrospective observa tional study meant that the NIV setting and monitoring depended on the patients' attending physicians. Differences in the NIV setting could affect the failure rate of NIV support. Second, some information regard ing the application of NIV was lacking, such as the leakage percentage and mask intolerance. Third, the sample size may have been inadequate, and it is possible that analysis of a larger population may identify more independent predictive factors for failure of NIV-assisted extubation. Fourth, this was a single-center study, and the results may thus have been influenced by our patients' baseline conditions, which may differ from those in other hospitals. The application of these results should thus be restricted to patients with similar characteristics to those in the present study. Additional studies are required to confirm the results of this research.
Conclusions
A high proportion (about 45.7%) of high-risk, medical critically ill patients may fail to respond to NIV support aimed at preventing reintubation after extubation. Patients with a diagnosis of pneumonia at ICU admission may be at particularly high risk of failure of NIVassisted extubation. Alternative methods are needed to prevent reintubation in this patient group.
